コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 proteins that mediate this protective effect remain poorly defined.
2 ffecting the accuracy of preoperative 4D-CTs remain poorly defined.
3 erning T-bet and CD11c expression in B cells remain poorly defined.
4 sponse to respiratory cryptococcal challenge remain poorly defined.
5 outcomes for pulmonary artery (PA) stenting remain poorly defined.
6 l virulence factors initiate these responses remain poorly defined.
7 molecular mechanisms that drive this process remain poorly defined.
8 carditis, yet their identities and functions remain poorly defined.
9 itness in epidemiological settings, however, remain poorly defined.
10 they affect the dynamics of subunit joining, remain poorly defined.
11 3 or ILC2s at surfaces such as the intestine remain poorly defined.
12 s is in its infancy and reasonable practices remain poorly defined.
13 aria, but the molecular and cellular details remain poorly defined.
14 of and response to this respiratory pathogen remain poorly defined.
15 rgo recognition of mono-ubiquitinated cargos remain poorly defined.
16 sensitivity to mismatched sequences in vivo remain poorly defined.
17 ne transcription, but the molecular pathways remain poorly defined.
18 extracranial systemic embolic events (SEEs) remain poorly defined.
19 molecular pathways driving postmitotic fates remain poorly defined.
20 ction of this hyporesponsive state, however, remain poorly defined.
21 tabolic and molecular control of hypertrophy remain poorly defined.
22 key features of this immune-mediated process remain poorly defined.
23 that regulate mTOR activity for myelination remain poorly defined.
24 orces that influence hematopoietic potential remain poorly defined.
25 ing its spread in the respiratory epithelium remain poorly defined.
26 observed in many human diseases and ageing, remain poorly defined.
27 omo-1 expression and its regulatory activity remain poorly defined.
28 atic steatosis, but the potential mechanisms remain poorly defined.
29 but molecular mechanisms of tumor resistance remain poorly defined.
30 metformin arrests cancer cell proliferation remain poorly defined.
31 The mechanisms underlying fetal lung injury remain poorly defined.
32 R promotes resistance or disease progression remain poorly defined.
33 ting energetics and longevity across tissues remain poorly defined.
34 isoxazolepropionic acid receptor (AMPAR-Abs) remain poorly defined.
35 tionships among Igh transcriptional elements remain poorly defined.
36 r, the signals instructing these adaptations remain poorly defined.
37 vaccine exists and correlates of protection remain poorly defined.
38 nisms by which H2O2 increases OPN expression remain poorly defined.
39 bolic requirements that support this process remain poorly defined.
40 enic program at central cholinergic synapses remain poorly defined.
41 lth, and rapidly activate reactive responses remain poorly defined.
42 ath mediates immune defense against Yersinia remain poorly defined.
43 prion protein (e.g. PrP(Sc) or PrP-Scrapie) remain poorly defined.
44 vary widely, and patient selection criteria remain poorly defined.
45 ific phenotype of SECs and development of SC remain poorly defined.
46 ng autoimmune disease in PKCdelta deficiency remain poorly defined.
47 However, the signaling properties of GPR124 remain poorly defined.
48 stone posttranslational modifications (PTMs) remain poorly defined.
49 ression of genes required in these processes remain poorly defined.
50 actors associated with outcome after surgery remain poorly defined.
51 ge activation and their functional phenotype remain poorly defined.
52 However, the underlying molecular mechanisms remain poorly defined.
53 acteristics and treatment of many AFI agents remain poorly defined.
54 recurrent AF is common and its risk factors remain poorly defined.
55 ading to HCC following chronic HCV infection remain poorly defined.
56 B regulate Ag-specific intestinal Th17 cells remain poorly defined.
57 responses to injury, but upstream activators remain poorly defined.
58 n cellular susceptibility to prion infection remain poorly defined.
59 The molecular mechanisms of emphysema remain poorly defined.
60 sease in the CNS during sterile inflammation remain poorly defined.
61 but the mechanisms mediating these functions remain poorly defined.
62 events in natural oral poliovirus infection remain poorly defined.
63 onocytes into profibrotic macrophages (Mphi) remain poorly defined.
64 ow the ribosome binds these upstream regions remain poorly defined.
65 cells promote human colorectal cancer (CRC) remain poorly defined.
66 molecular mechanisms initiating this disease remain poorly defined.
67 response to environmental cues that to date remain poorly defined.
68 f A. fumigatus-induced human Th cell subsets remain poorly defined.
69 nd the signals that specify MN subtype fates remain poorly defined.
70 al pathology, but the biochemical mechanisms remain poorly defined.
71 brane environment, the underlying mechanisms remain poorly defined.
72 nary heart disease (CHD), but the mechanisms remain poorly defined.
73 -autosome ratio (X:A), but molecular factors remain poorly defined.
74 precise factors regulating these transitions remain poorly defined.
75 lar effectors underlying tumor dissemination remain poorly defined.
76 g rhythmic lipid synthesis in the dark cycle remain poorly defined.
77 irus (RABV) pathogenicity and immunogenicity remain poorly defined.
78 to intra-pulmonary vaccinia virus infection remain poorly defined.
79 erminants that control CD79b gene expression remain poorly defined.
80 cells during IVD maturation and aging still remain poorly defined.
81 termine the differentiation of these subsets remain poorly defined.
82 s underlying plerixafor-induced neutrophilia remain poorly defined.
83 ble polyubiquitin chains on their substrates remain poorly defined.
84 ng the antigen sensitivity of CD8(+) T cells remain poorly defined.
85 mbranes must be processed by mechanisms that remain poorly defined.
86 te cancer following radical ablation therapy remain poorly defined.
87 synapses when neural circuits are remodeled remain poorly defined.
88 However, the nature and biogenesis of VCCs remain poorly defined.
89 NLRP3 senses inflammasome-activating stimuli remain poorly defined.
90 te the variety of cargoes during endocytosis remain poorly defined.
91 However, the mechanisms of this phenomenon remain poorly defined.
92 nstream steps required for cilia orientation remain poorly defined.
93 anisms and effective intervention strategies remain poorly defined.
94 e signaling pathways leading to these events remain poorly defined.
95 s therapeutic targets for Myc-driven cancers remain poorly defined.
96 ctors that initiate DLK/JNK pathway activity remain poorly defined.
97 n of IL-1alpha in response to L. pneumophila remain poorly defined.
98 te efflux and the ensuing behavioral effects remain poorly defined.
99 signals that mediate metabolic reprogramming remain poorly defined.
100 ial benefits of targeting them with vaccines remain poorly defined.
101 al dynamics of opioid signaling in the brain remain poorly defined.
102 tribute to the beneficial effects of aspirin remain poorly defined.
103 and initiate the angiogenic switch in tumors remain poorly defined.
104 ut the underlying transcriptional mechanisms remain poorly defined.
105 s governing glial responses to neural injury remain poorly defined.
106 process are known, its underlying mechanisms remain poorly defined.
107 hat suppress the production of this cytokine remain poorly defined.
108 ling events during synapse formation in vivo remain poorly defined.
109 tiation, but their origins and relationships remain poorly defined.
110 major regulators under conditions of stress remain poorly defined.
111 nt, hematopoietic recovery in these patients remain poorly defined.
112 butions of other types of commensal microbes remain poorly defined.
113 oteins and how they assemble in subcomplexes remain poorly defined.
114 , and polarity, yet its mechanisms of action remain poorly defined.
115 erlying Numb function in a stem cell setting remain poorly defined.
116 equent compartments of the secretory pathway remain poorly defined.
117 molecular mechanisms employed in the nucleus remain poorly defined.
118 helminth infection; however, their functions remain poorly defined.
119 ecific effects of trisomy 21 on the skeleton remain poorly defined.
120 ng mechanisms leading to new spine outgrowth remain poorly defined.
121 ms underlying RyR2 dysregulation in diabetes remain poorly defined.
122 al cell lineage relationships that currently remain poorly defined.
123 T cells and diseases mediated by T(H)9 cells remain poorly defined.
124 ating cell proliferation and differentiation remain poorly defined.
125 lar mechanisms associated with Robo function remain poorly defined.
126 ationship to the canonical NF-kappaB pathway remain poorly defined.
127 t or positive selection in mammalian genomes remain poorly defined.
128 get antigens of Salmonella-specific immunity remain poorly defined.
129 ion, the determinants of switching frequency remain poorly defined.
130 d function of the underlying neural circuits remain poorly defined.
131 antiplatelet therapy after coronary stenting remain poorly defined.
132 astoma metastasis although precise functions remain poorly defined.
133 iggering nonalcoholic steatohepatitis (NASH) remain poorly defined.
134 ory response during Gram-negative bacteremia remain poorly defined.
135 T pacing loss and their relative frequencies remain poorly defined.
136 l nicotinic acetylcholine receptors (nAChRs) remain poorly defined.
137 ty, the mechanisms regulating its expression remain poorly defined.
138 echanisms regulating the global SUMO balance remain poorly defined.
139 d cell biological consequences of AMPylation remain poorly defined.
140 NDK activity or alternative mechanisms that remain poorly defined.
141 Essential aspects of ultrafiltration remain poorly defined.
142 r antigens targeted in successful treatments remain poorly defined.
143 e specific species associated with GVHD risk remain poorly defined.
144 However, the mechanisms leading to swelling remain poorly defined.
145 alpha), but the cellular actions of XLalphas remain poorly defined.
146 pancreatic cancer progression and metastasis remain poorly defined.
147 However, the key drivers of this process remain poorly defined.
148 ugh the cellular contributors to CNS disease remain poorly defined.
149 arsenic and the associated immune mechanisms remain poorly defined.
150 ces, and therapeutic options related to FALD remain poorly defined.
151 the metabolic requirements for this process remain poorly defined.
152 atures that constitute an effective response remain poorly defined.
153 or admission to the ICU and adverse outcomes remain poorly defined.
154 cular components that stabilize basal bodies remain poorly defined.
155 ity but the mechanisms of IL-36Ra activation remain poorly defined.
156 the clinical and biological features of WDSM remain poorly defined.
157 ing logic governing these concurrent changes remain poorly defined.
158 isorders, although the underlying mechanisms remain poorly defined.
159 the sources and regulation of these signals remain poorly defined.
160 distinctive role in the inflammatory process remain poorly defined.
161 terogeneity of DNA methylation among tumours remain poorly defined.
162 brane traffic, but the underlying mechanisms remain poorly defined.
163 for the action of ROS in intestinal diseases remain poorly defined.
164 unctional properties of this T cell response remain poorly defined.
165 defects of antimycobacterial immunity, which remain poorly defined.
166 cruitment mechanisms to the abdominal cavity remain poorly defined.
167 xogenous cells best heal orthopedic injuries remain poorly defined.
168 long-term outcomes after surgical resection remain poorly defined.
169 echanisms underlying these sensory functions remain poorly defined.
170 in the mammalian small intestinal epithelium remain poorly defined.
171 h mechanical stimuli regulate mTOR signaling remain poorly defined.
172 or and its regulation by drug-like compounds remain poorly defined.
173 rs that mediate their developmental function remain poorly defined.
174 h Ras can promote such a senescent phenotype remain poorly defined.
175 ature brain, the role of Sema7A in the adult remains poorly defined.
176 The molecular mechanism for this association remains poorly defined.
177 cell function but its role in lymphoid cells remains poorly defined.
178 sm by which TNFalpha promotes neuronal death remains poorly defined.
179 s, but its function in adult skeletal muscle remains poorly defined.
180 nic impairment and the prognosis of ischemia remains poorly defined.
181 ough the exact cause and effect relationship remains poorly defined.
182 owever, its role in modulating IFN responses remains poorly defined.
183 e regulatory network whose precise circuitry remains poorly defined.
184 , but the physical basis for these reactions remains poorly defined.
185 , the life span of individual memory B cells remains poorly defined.
186 cells (Tregs), but the underlying mechanism remains poorly defined.
187 s, the role of B cells in cutaneous immunity remains poorly defined.
188 own upstream regulators of the Hippo pathway remains poorly defined.
189 , the spatiotemporal organization of mitosis remains poorly defined.
190 nged (EVI1-r) acute myeloid leukemias (AMLs) remains poorly defined.
191 pecific gene regulation during embryogenesis remains poorly defined.
192 y of alphaviruses to induce bone pathologies remains poorly defined.
193 mmune suppression, but their clinical impact remains poorly defined.
194 l receptor (TCR)-mediated ligand recognition remains poorly defined.
195 cellular function(s) of APOL1 in human cells remains poorly defined.
196 -bet in infections with differential outcome remains poorly defined.
197 but its role in vegetative tissues of plants remains poorly defined.
198 he initiation and progression of the disease remains poorly defined.
199 fluence memory CD8(+) T cell differentiation remains poorly defined.
200 molecular basis for CPSF-AAUAAA interaction remains poorly defined.
201 has been reported on neutrophils, their role remains poorly defined.
202 etralogy of Fallot, the scope of the problem remains poorly defined.
203 ty appear to be well understood, its regulon remains poorly defined.
204 ad to fibrosis following HCV infection still remains poorly defined.
205 tivated protein kinase (AMPK) and myogenesis remains poorly defined.
206 The impact on hospital course and outcome remains poorly defined.
207 bstrates--the PARKIN-dependent ubiquitylome--remains poorly defined.
208 cysteine protease whose biological function remains poorly defined.
209 ifferentiation with implications in fibrosis remains poorly defined.
210 How the virus achieves this remains poorly defined.
211 symptomatic overlap, the underlying etiology remains poorly defined.
212 lymphocytes primed against tumor neoantigens remains poorly defined.
213 nd mechanism that regulates this interaction remains poorly defined.
214 nsfusion) on perioperative surgical outcomes remains poorly defined.
215 ostasis, wound healing, and tumor initiation remains poorly defined.
216 this endogenous MHC class II loading pathway remains poorly defined.
217 n SHP-1 cause inflammatory disease in humans remains poorly defined.
218 genesis of many diseases, but its regulation remains poorly defined.
219 proteins within the organelle in most cases remains poorly defined.
220 rage lesion triggers pathophysiology in vivo remains poorly defined.
221 nate immune cells respond to allotransplants remains poorly defined.
222 owever, the molecular basis of this function remains poorly defined.
223 efore, the natural cellular identity of MSCs remains poorly defined.
224 interhospital population-based transmission remains poorly defined.
225 ariant chain, is one such molecule; its role remains poorly defined.
226 r; however, O-GlcNAcylation in other cancers remains poorly defined.
227 ut the interplay between these effector arms remains poorly defined.
228 of these transcription factors is regulated remains poorly defined.
229 composition of intracellular parasite stages remains poorly defined.
230 1890s, but the genetic basis of these traits remains poorly defined.
231 ession of non-small cell lung cancer (NSCLC) remains poorly defined.
232 e contribution of individual enteropathogens remains poorly defined.
233 ource of bone-forming cells in these lesions remains poorly defined.
234 molecular architecture of a GPCR/GRK complex remains poorly defined.
235 how these proteins function mechanistically remains poorly defined.
236 ic pathogens, but its impact on pathogenesis remains poorly defined.
237 ptional network that controls these patterns remains poorly defined.
238 , the physiological role of the CD1 proteins remains poorly defined.
239 s explored for vaccine, the underlying event remains poorly defined.
240 ough the mechanistic basis of discrimination remains poorly defined.
241 ponse contributes to inflammatory regulation remains poorly defined.
242 e proportion of the population, its etiology remains poorly defined.
243 , the role of this subcellular translocation remains poorly defined.
244 nsfusion) on perioperative surgical outcomes remains poorly defined.
245 ignalling pathways and epigenetic regulators remains poorly defined.
246 organic dust exposure independent of smoking remains poorly defined.
247 nscriptional logic underpinning this process remains poorly defined.
248 le of the immunoproteasome in neuropathology remains poorly defined.
249 akaryocyte-erythroid progenitor (MEP), which remains poorly defined.
250 underpinning its reversible deubiquitination remains poorly defined.
251 lying TOT preferential recruitment of the ER remains poorly defined.
252 lly modify SV pools to match network demands remains poorly defined.
253 interactions with the intestinal epithelium remains poorly defined.
254 e of autophagy in doxorubicin cardiomyopathy remains poorly defined.
255 ients undergoing surgery (surgical patients) remains poorly defined.
256 However, the mechanism of this process remains poorly defined.
257 entiations on Ag processing and presentation remains poorly defined.
258 ification in renal transplant patients still remains poorly defined.
259 multiple time scales, and their relationship remains poorly defined.
260 these processes are mechanistically related remains poorly defined.
261 he molecular nature of this relationship has remained poorly defined.
262 se (pol) theta, an A family polymerase, have remained poorly defined.
263 osis, the connecting molecular pathways have remained poorly defined.
264 s)/AIDS patient postoperative mortality have remained poorly defined.
265 ping T cells, but the responsible DC subsets remained poorly defined.
266 but its molecular architecture has thus far remained poorly defined.
267 e research, the functions of Hxt8-Hxt17 have remained poorly defined.
268 and function of the tumor immune environment remain poorly defined and need investigation, particular
270 identified, the detailed molecular mechanism remains poorly defined and requires further clarificatio
271 ertebrate species, their mechanism of action remains poorly defined and their role in vivo unknown.
272 nship between age and physiological function remains poorly defined and there are no physiological ma
273 the importance of golgin-mediated tethering remains poorly defined, and alternative functions for go
276 intrauterine infection and fetal lung injury remain poorly defined, but may hold the key to preventin
277 ctions of individual RSK family members have remained poorly defined, despite being potential therape
278 cription by human RNA polymerase II (Pol II) remain poorly defined due to a lack of quantitative appr
279 ich PriC drives DNA replication restart have remained poorly defined due to the limited structural in
280 well characterized during neurogenesis, but remain poorly defined during neural stem cell commitment
281 and unwinding via molecular mechanisms that remain poorly defined for most enzyme subfamilies within
282 r, the prognosis of young-onset colon cancer remains poorly defined given significant age-related dem
283 which are critical for long-term protection, remain poorly defined, impeding our understanding of nat
284 rminants of hnRNP A1 splice site recognition remain poorly defined in HIV-1, thus precluding a detail
288 echanisms underlying this multifunctionality remain poorly defined in vivo Using telencephalon develo
293 epidemiology of campylobacteriosis outbreaks remains poorly defined, largely due to limitations in th
294 n-enveloped virus cell entry, in comparison, remains poorly defined, particularly for large complex c
295 matopoietic stem cell transplantation (HSCT) remain poorly defined, partly because immunity against m
296 sociated changes in the coronary vasculature remain poorly defined primarily due to the lack of high
298 for the anti-silencing activity of UCOEs has remained poorly defined, we interrogated various CBX3 su
299 from other ion channels and their structure remains poorly defined, which impedes detailed study of
300 influence the development of cancer, but it remains poorly defined with regard to pancreatic cancer,
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。